| 1 |
国家卫生健康委关于修订新型冠状病毒肺炎英文命名事宜的通知[EB/OL]. [2020-2-22].
URL
|
| 2 |
Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J/OL]. Lancet, January 24, 2020,
URL
|
| 3 |
CHINET中国细菌耐药监测结果 [DB/OL].
URL
|
| 4 |
Van loon K, Voor In't Holt AF, Vos MC. Clinical epidemiology of carbapenem-resistant Enterobacteriaceae: a systematic review and meta-analyses[J]. Antimicrob Agents Chemother, 2017, 62(1): AAC.01730-17.
|
| 5 |
国家卫生健康委员会.关于印发新型冠状病毒肺炎诊疗方案(试行第六版)的通知[EB/OL].
URL
|
| 6 |
Uyeki TM, Bernstein HH, Bradley JS, et al. Pavia AT Clinical practice guidelines by the infectious diseases society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal infuenzaa[J]. Clin Infect Dis, 2019, 68: 895-902.
|
| 7 |
Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem resistant Enterobacteriaceae infections [DB/OL]. Clinical Microbiology and Infection.
URL
|
| 8 |
Pittet D, Boyce J, Aller ganzi B (eds) Hand hygiene: a handbook for medical professionals [M]. New York: Wiley, 2017: 317-323.
|
| 9 |
European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe 2016 [R]. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC, 2017.
|
| 10 |
Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial[J]. Lancet Infect Dis, 2018, 18(3): 285-295.
|
| 11 |
Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs. class A serine carbapenemases[J]. J Med Chem, 2015, 58(9): 3682-3692.
|
| 12 |
Papp-Wallace KM, Barnes MD, Alsop J, et al. Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae[J]. Antimicrob Agents Chemother, 2018, 62(6): e00174-18.
|
| 13 |
Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. EPIC Study Group. Once-Daily Plazomicin for Complicated Urinary Trat Infections[J]. N Engl J Med. 2019, 380(8): 729-740.
|
| 14 |
Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality[J]. Clin Microbiol Infect, 2013, 19(1): E23-E30.
|
| 15 |
De Pascale G, Montini L, Pennisi MA, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria[J]. Critical Care, 2014, 18: R90.
|
| 16 |
Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria[J]. Int J Antimicrob Agents, 2014, 43: 52-59.
|
| 17 |
Papadimitriou-Olivgeris M, Fligou F, Bartzavali C, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality[J]. Eur J Clin Microbiol Infect Dis, 2017, 36: 1125-1131.
|
| 18 |
Zusman O, Altunin S, Koppel F, et al. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis[J]. J Antimicrob Chemother, 2017, 72(1): 29-39.
|